Innovent Biologics Inc (6IB) — Capital Reinvestment Ratio
Innovent Biologics Inc (6IB) has a Capital Reinvestment Ratio of 0.97x as of December 2020, meaning it reinvests 1% of its operating cash flow (€217.96 Million) in capital expenditures (€211.14 Million). Check Innovent Biologics Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Innovent Biologics Inc Capital Reinvestment Ratio (2023–2025)
This chart tracks Innovent Biologics Inc's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see Innovent Biologics Inc cash flow conversion.
Annual Capital Reinvestment Ratio for Innovent Biologics Inc (2023–2025)
Year-by-year Capital Reinvestment Ratio for Innovent Biologics Inc from 2023 to 2025. See 6IB FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.07x | €10.00 Billion | €683.27 Million | ▼ -94.8% |
| 2024 | 1.33x | €1.29 Billion | €1.71 Billion | ▼ -85.8% |
| 2023 | 9.36x | €147.81 Million | €1.38 Billion | — |